Recent News

• 02.05.2025 - Viracta Therapeutics Announces Wind Down of Operations
• 12.26.2024 - Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
• 11.13.2024 - Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
• 11.06.2024 - Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Recent Filings

• 02.05.2025 - 8-K Current report
• 12.26.2024 - EX-99.1 EX-99.1
• 11.27.2024 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]